Elevance Health stock trades around $403 as Q2 2026 earnings beat backs analyst targets
Published on 08/25/2026 at 14:13 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Elevance Health Inc. (US2855211023) stock is trading close to $403 as of August 24, 2026, with investors weighing a solid Q2 2026 earnings beat against a still-muted share move and a valuation that sits below consensus analyst price targets. Elevance Health reported Q2 2026 revenue of $49.83 billion and earnings per share of $7.45 in the quarter ended June 30, 2026, beating market expectations and underpinning full-year guidance benchmarks, as highlighted in a recent healthcare overview recent coverage.
Q2 2026 earnings beat supports full-year trajectory
Per the same overview dated August 24, 2026, Elevance Health delivered Q2 2026 revenue of $49.83 billion for the quarter ended June 30, 2026, essentially flat versus the same period a year earlier but slightly ahead of analyst expectations of $48.88 billion, a beat of 2.5 percent versus consensus. Earnings per share in Q2 2026 came in at $7.45, which was $1.24 above the consensus estimate of $6.21, signaling stronger profitability than analysts had modeled for the period and demonstrating cost discipline in the company’s managed-care operations Q2 2026 earnings detail.
The same Q2 2026 overview notes that analysts tracking Elevance Health currently forecast full-year 2026 earnings per share of 27.18, implying that the Q2 result represents meaningful progress toward that target while still leaving room for execution in the second half of the year. In effect, the Q2 2026 beat against quarterly consensus reinforces market confidence that Elevance Health can deliver the full-year EPS expectation, even though revenue growth in the period was described as essentially flat compared with Q2 2025. From an investor perspective, the combination of a strong earnings beat and subdued top-line growth places the emphasis on margin management and underwriting discipline across Elevance Health’s health benefits portfolio.
Analyst consensus points to upside versus current price
Across several recent filings and coverage updates summarized in the same August 24, 2026 article, Elevance Health currently carries a consensus rating labeled Moderate Buy, with an average analyst price target of $440.90. That target stands above the latest trading region of roughly $403 as of August 24, 2026, indicating a gap between the present market valuation and the level analysts view as fair value based on their earnings models and sector comparisons analyst consensus overview.
A recent stock outlook note on Elevance Health explains that the mean price target of $445.71 represents a 11.6 percent premium to the company’s current price levels, highlighting that Wall Street’s view embeds upside from recent trading regions stock outlook detail. Comparing the $403 trading region to the $440.90 average price target implies an upside of close to 9.4 percent if the shares were to move toward the average target, and comparing the same price region to the $445.71 mean target points to even more potential appreciation if the consensus scenario plays out. For valuation context, the August 24, 2026 ad-hoc overview notes that at this price region, combined with the full-year EPS expectation of 27.18, Elevance Health trades at a price-to-earnings multiple that aligns the company broadly with other large-cap managed-care peers.
Dividend stream and capital return add to the thesis
Beyond earnings and price targets, Elevance Health’s capital return program remains an additional element for investors assessing the stock as of late August 2026. Several recent investment filings summarizing the company point out that Elevance Health declared a quarterly dividend of $1.72 per share, translating to an annualized dividend of $6.88 and a dividend yield of 1.7 percent based on recent trading levels. The dividend payout ratio is described as 30.58 percent, suggesting that Elevance Health is returning a portion of earnings to shareholders while retaining sufficient capital for growth initiatives and balance-sheet strength dividend and payout context.
For investors following the managed-care segment, the combination of a 1.7 percent dividend yield and a Moderate Buy consensus rating implies that Elevance Health is viewed as a steady income and growth candidate rather than a pure high-growth name. With analysts forecasting 27.18 EPS for full-year 2026 and an annual dividend of $6.88, the implied payout ratio underscores that management is balancing shareholder distributions with reinvestment in operations, technology and member services. In this framework, the Q2 2026 earnings beat serves as a key data point demonstrating that Elevance Health can support both ongoing dividend payments and longer-term EPS growth targets.
Institutional activity highlights confidence in the managed-care model
Recent institutional filings capture increased interest in Elevance Health shares, reinforcing the narrative that large investors remain engaged with the stock. One filing dated August 25, 2026 notes that a wealth management firm invested $41.31 million in Elevance Health, while another filing reports a separate institution acquiring more than 1.7 million shares. These moves are described alongside data indicating that analysts as a group maintain the Moderate Buy rating and the average price target at $440.90, suggesting that institutional flows are aligned with the constructive analyst stance reported in the filings institutional investment note.
Institutional accumulation can matter for Elevance Health because the company’s managed-care business depends on stable long-term capital to support its underwriting and member services platforms. When filings show new investments measured in tens of millions of dollars and share counts in the high hundreds of thousands or low millions, that pattern often signals that large investors are comfortable with the company’s risk profile, regulatory environment and earnings trajectory. Against the backdrop of the Q2 2026 earnings beat and the dividend stream, these institutional purchases contribute to a narrative in which Elevance Health stands as a core holding within many healthcare and broad-market portfolios, even as the share price remains short of analyst target levels.
Core health benefits offering underpins earnings power
Elevance Health’s core business centers on health benefits, with the company serving tens of millions of medical members through managed-care plans that connect individuals, employers and public programs to broad provider networks. A healthcare earnings review published on August 24, 2026 notes that Elevance Health, formerly known as Anthem until its 2022 rebranding, is one of America’s largest health insurers and that the company’s Q2 2026 revenues of $49.83 billion were flat year on year but ahead of analyst expectations by 2.5 percent, reflecting resilient demand for its managed-care offerings despite competitive and regulatory pressures healthcare sector comparison.
Within that review, Elevance Health is described as having lost 469,000 customers in the quarter ended June 30, 2026, ending up with 44.95 million members, a reminder that member counts can fluctuate even when revenue and earnings trends remain healthy. The report also indicates that the stock was down 5.6 percent since reporting Q2 2026 results and traded at $403.03 around August 24, 2026, aligning with the price region referenced in the ad-hoc overview and providing a concrete snapshot of how the market responded to the earnings release. For investors, those member and price moves highlight that Elevance Health’s earnings power is not solely a function of sheer member growth but also depends on pricing, service mix, medical cost management and administrative efficiency across its diverse health benefits portfolio.
Flagship product focus: network-based managed-care plans
A representative product within Elevance Health’s offering is its network-based managed-care plan platform, which provides health insurance coverage to individuals and employer groups by contracting with hospitals, physicians and other providers at negotiated rates. These managed-care plans often feature integrated care coordination, preventive services and digital engagement tools that aim to improve outcomes while controlling costs. By leveraging data analytics and claims history, Elevance Health can design benefit structures that balance affordability for members with sustainable margins for the company, a dynamic that directly feeds into the EPS figures and revenue stability highlighted in the Q2 2026 results.
From a member standpoint, network-based managed-care plans allow policyholders to access a curated provider network that may include incentives for using in-network services, telemedicine options and disease management programs. For Elevance Health, the scale of its provider relationships and its experience in underwriting risk across large populations provide competitive advantages versus smaller insurers. As Q2 2026 figures show, the company can maintain revenues around $49.83 billion and deliver EPS of $7.45 even when member counts decline, underscoring that the managed-care product architecture and pricing strategy are central to sustaining earnings, dividend capacity and alignment with analyst expectations.
Elevance Health stock valuation and price snapshot
In terms of pure valuation metrics, the August 24, 2026 ad-hoc overview explains that with Elevance Health stock trading close to $403 and analysts expecting full-year 2026 EPS of 27.18, the shares imply a price-to-earnings multiple that places the company broadly in line with other large-cap managed-care peers. While precise peer multiples vary, the indication that Elevance Health’s P/E ratio sits within a normal range for its segment suggests that the stock is not extended on earnings grounds even after the Q2 2026 beat. Instead, the gap between the current price region near $403 and the average analyst target of $440.90, as well as the mean target of $445.71, points to a scenario where upside potential exists if the company continues to execute on its earnings and capital return plans.
Market data from recent filings shows Elevance Health stock opening at $402.62 on August 25, 2026, situating the price slightly below the $403 region referenced for August 24, 2026 and confirming that the shares are trading in a relatively tight band around the $400 level at the start of the new trading session August 25, 2026 opening price. With the annual dividend of $6.88 producing a yield of 1.7 percent on these price levels, and analysts sustaining a Moderate Buy consensus, Elevance Health’s stock profile in late August 2026 combines income, earnings visibility and analyst-backed upside potential, even as revenue growth remains modest and member counts fluctuate.
Closing view on Elevance Health stock
As of August 24, 2026, Elevance Health stock trades close to $403 on the New York Stock Exchange, reflecting investor reactions to the Q2 2026 earnings beat, the stable revenue base and the ongoing dividend stream described in recent coverage. With an opening price of $402.62 on August 25, 2026 and an average analyst price target of $440.90, the shares continue to sit below consensus value estimates while offering a 1.7 percent dividend yield and alignment with managed-care peer valuations, giving investors a data-rich basis for assessing the balance between current price levels and the earnings and dividend trajectory ahead.
Read more
More on Elevance Health stock at the latest healthcare earnings and analyst overview pages that detail Q2 2026 revenue, EPS performance, member trends and valuation context for the managed-care segment.
Fact box
Company: Elevance Health Inc.
ISIN: US2855211023
Ticker: ELV
Exchange: New York Stock Exchange
Price (as of August 25, 2026, opening): $402.62 USD
Sector / Industry: Health care - Managed care / Health benefits
Index membership: S&P 500
